656 filings
Page 4 of 33
6-K
b6q4 blk41
3 Nov 22
Immutep Late-Breaking Abstract Accepted for Oral Presentation
6:56pm
6-K
bqis0nu9lrsv1lr
27 Oct 22
Immutep Announces Independent Data Monitoring Committee Positive
9:52pm
6-K
wodla p7ox768mo
25 Oct 22
Immutep Quarterly Activities Report & Appendix 4C
6:41pm
6-K
vqqryo wthn
6 Oct 22
Immutep Announces Abstracts Accepted for Presentation at Catherine Strong, Citadel-MAGNUS
6:49am
6-K
5bv2u rqs3mvc
5 Oct 22
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic
6:05am
6-K
odnu1hm
23 Sep 22
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
6:05am
6-K
ujnw0hbwlmv939uxkl4
14 Sep 22
Immutep Clinical Development Update for its First-in-Class
8:20pm
6-K
mhbdf9l5kkt0ft5x3y
13 Sep 22
Immutep Appoints LAG-3 Pioneer, Frédéric Triebel to Board
7:57pm
6-K
qrbtchyt
6 Sep 22
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
6:57pm
6-K
pczx 7wi68
1 Sep 22
Preliminary final report
5:06pm
6-K
ec1w32gl9g4so3gi
30 Aug 22
Current report (foreign)
7:17pm
6-K
r7a6d04
1 Aug 22
Immutep Reports New Positive Interim Data from its Phase II Study
8:03pm
6-K
a89lxnv8q8kvfs03q
28 Jul 22
Immutep Quarterly Activities Report & Appendix 4C
7:41pm
6-K
gerfdzr1
6 Jul 22
Current report (foreign)
8:47pm
6-K
k7tsadjo
27 Jun 22
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
7:13pm
6-K
qhnnyu8kzq
6 Jun 22
Immutep reports positive Overall Response Rate
7:31pm
6-K
m8bzby4
31 May 22
Immutep Announces Publication of TACTI-002
12:00am
6-K
sl1r8mz7
18 May 22
Immutep Appoints Leading Oncologists to its Clinical Advisory Board
6:07am
6-K
61c2jssf
4 May 22
Immutep presents new and significant data from the AIPAC study
7:14pm